A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)

Study Identifier
MAF/AGN/OPH/RET/010
CT.gov Identifier
NCT01445626
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Macular Edema
    • Study Drug
  • dexamethasone intravitreal implant 0.7 mg
    • Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Macular oedema in the study eye due to BRVO or CRVO * Received at least 2 OZURDEX® injections in the study eye
    Exclusion Criteria:
    * Received OZURDEX® injections as part of or during any clinical study

    Protocol Summary

    This study will use retrospective data to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular oedema due to Retinal Vein Occlusion (RVO).

    Study Locations

    Location
    Status
    Location
    Münster, Germany
    Status
    Not applicable